These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32926517)

  • 1. Successful treatment of symptomatic dermographism in an adolescent with omalizumab.
    Kaya Erdogan H; Ağaoğlu E; Acer E; Batan T; Saracoglu ZN
    Dermatol Ther; 2020 Nov; 33(6):e14304. PubMed ID: 32926517
    [No Abstract]   [Full Text] [Related]  

  • 2. Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial.
    Maurer M; Schütz A; Weller K; Schoepke N; Peveling-Oberhag A; Staubach P; Müller S; Jakob T; Metz M
    J Allergy Clin Immunol; 2017 Sep; 140(3):870-873.e5. PubMed ID: 28389391
    [No Abstract]   [Full Text] [Related]  

  • 3. Omalizumab as Third-Line Therapy for Urticaria During Pregnancy.
    Ensina LF; Cusato-Ensina AP; Camelo-Nunes IC; Solé D
    J Investig Allergol Clin Immunol; 2017; 27(5):326-327. PubMed ID: 29057743
    [No Abstract]   [Full Text] [Related]  

  • 4. Effectiveness of omalizumab in severe solar urticaria.
    de Dios-Velázquez Á; González-de Arriba M; Beteta-Gorriti V; Macías E; Campanón-Toro V; Dávila I
    Ann Allergy Asthma Immunol; 2016 Mar; 116(3):260-2. PubMed ID: 26803538
    [No Abstract]   [Full Text] [Related]  

  • 5. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria.
    Straesser MD; Oliver E; Palacios T; Kyin T; Patrie J; Borish L; Saini SS; Lawrence MG
    J Allergy Clin Immunol Pract; 2018; 6(4):1386-1388.e1. PubMed ID: 29175369
    [No Abstract]   [Full Text] [Related]  

  • 6. Refractory solar urticaria successfully treated with omalizumab with normalization of phototest.
    Combalia A; Fernández-Sartorio C; Aguilera P
    Actas Dermosifiliogr; 2017; 108(6):593-594. PubMed ID: 28168968
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of omalizumab 150 mg/month as a maintenance dose in patients with severe chronic spontaneous urticaria showing a prompt and complete response to the drug.
    Asero R
    Allergy; 2018 Nov; 73(11):2242-2244. PubMed ID: 29989179
    [No Abstract]   [Full Text] [Related]  

  • 8. Omalizumab re-treatment rates in chronic spontaneous urticaria.
    Khan S; Sholtysek S
    Eur Ann Allergy Clin Immunol; 2020 May; 52(4):187-189. PubMed ID: 32378397
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria.
    Giménez-Arnau AM; Toubi E; Marsland AM; Maurer M
    J Eur Acad Dermatol Venereol; 2016 Jul; 30 Suppl 5():25-32. PubMed ID: 27286500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of refractory cholinergic urticaria with omalizumab.
    Koumaki D; Seaton ED
    Int J Dermatol; 2018 Jan; 57(1):114. PubMed ID: 29057464
    [No Abstract]   [Full Text] [Related]  

  • 11. Elevated baseline D-dimer plasma levels are associated with a prompt response to omalizumab in patients with severe CSU.
    Asero R; Marzano AV; Ferrucci S; Cugno M
    J Allergy Clin Immunol Pract; 2017; 5(6):1740-1742. PubMed ID: 28866106
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful treatment of occupational delayed pressure urticaria and angioedema with omalizumab.
    Geller M
    Ann Allergy Asthma Immunol; 2016 Jan; 116(1):81-2. PubMed ID: 26602491
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of Omalizumab Treatment with Concomitant Antihistamines as Needed for Moderate, Refractory Chronic Spontaneous Urticaria.
    Nettis E; Cegolon L; Macchia L; Zaza I; Calogiuri G; Di Leo E
    Acta Derm Venereol; 2018 Apr; 98(4):446-448. PubMed ID: 29362811
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of omalizumab in severe chronic spontaneous urticaria: Real life data from a Greek tertiary center.
    Kyriakou A; Trigoni A; Sotiriadis D; Patsatsi A
    Dermatol Ther; 2018 Nov; 31(6):e12739. PubMed ID: 30194796
    [No Abstract]   [Full Text] [Related]  

  • 15. Omalizumab therapy in a patient with cronic spontaneous urticaria, ulcerative colitis, hypereosinophilia and prurigo Besnier: a case report.
    Grieco T; Chello C; Faina V; Gomes VV; Alei L; Sernicola A; Panasiti V; Calvieri S
    J Dermatolog Treat; 2018; 29(sup3):10-13. PubMed ID: 30256692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab use during pregnancy for CIU: a tertiary care experience.
    Cuervo-Pardo L; Barcena-Blanch M; Radojicic C
    Eur Ann Allergy Clin Immunol; 2016 Jul; 48(4):145-6. PubMed ID: 27425170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab for chronic spontaneous urticaria: a boon for sufferers, but there are unanswered questions.
    Greaves MW
    Br J Dermatol; 2015 Aug; 173(2):321. PubMed ID: 26346076
    [No Abstract]   [Full Text] [Related]  

  • 18. Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study.
    Casale TB; Win PH; Bernstein JA; Rosén K; Holden M; Iqbal A; Trzaskoma BL; Yang M; Antonova EN; Murphy T; Scarupa MD; Sofen H; Kaplan A
    J Am Acad Dermatol; 2018 Apr; 78(4):793-795. PubMed ID: 29037993
    [No Abstract]   [Full Text] [Related]  

  • 19. Omalizumab for the treatment of chronic spontaneous urticaria in clinical practice.
    Bongiorno MR; Crimi N; Corrao S; Allotta A; Arena A; Brusca I; Heffler E; Malara G; Milioto M; Pistone G; Porto M; Raia E; Valenti G
    Ann Allergy Asthma Immunol; 2016 Dec; 117(6):703-707. PubMed ID: 27720581
    [No Abstract]   [Full Text] [Related]  

  • 20. Real-life treatment of cholinergic urticaria with omalizumab.
    Altrichter S; Chuamanochan M; Knoth H; Asady A; Ohanyan T; Metz M; Maurer M
    J Allergy Clin Immunol; 2019 Feb; 143(2):788-791.e8. PubMed ID: 30312709
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.